Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP/Chief Medical Officer | December 22, 2021 | December 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date December 22, 2021 · Filed December 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,675 |
Reported balance
After 2021-12-22 transaction · row 1
1 source rowRow 1 · 2021-12-22 · Grant · Acquired 4,243 · Balance 22,675 F1: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 2, 2022, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 2, 2022, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2021 Filed Dec 23, 2021 21:10 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011226 · edgar.xml · nonDerivative · entry 1 Michaels Lisa Anne · CIK 0001830610 · EVP/Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,675 F1 · kind: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 2, 2022, subject to continued service. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:26 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,568 | $38.33 | $60,101.44 |
DisclosureSEC source: 0001179110-21-010113 · edgar.xml · nonDerivative · entry 1 Michaels Lisa Anne · CIK 0001830610 · EVP/Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,432 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on November 11, 2021, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 9, 2021. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:28 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $30.41 | $0.00 |
DisclosureSEC source: 0001179110-20-010969 · edgar.xml · derivative · entry 2 Michaels Lisa Anne · CIK 0001830610 · EVP/Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-11-08 F2 · derivative.exercise_date: This option was granted on November 9, 2020 and is scheduled to vest over four years, with 25% of the shares to vest on November 9, 2021 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through November 9, 2024. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:28 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-010969 · edgar.xml · nonDerivative · entry 1 Michaels Lisa Anne · CIK 0001830610 · EVP/Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on November 9, 2021 continuing through November 9, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.